In patients of NSCLC carrying KRAS and STK11 mutations, as well as Serine/Threonine Kinase 11 (STK11), Kelch-like ECH-associated protein 1 (KEAP1), tumor protein p53 (TP53), and/or strong PD-L1 expression (≥50%), bevacizumab in combination with atezolizumab and chemotherapy (carboplatin and paclitaxel) could serve as the first-line treatment [68]. Here, TP53 is linked to non-small cell lung carcinoma.